HS
INO icon

Horan Securities’s Inovio Pharmaceuticals INO Stock Holding History

Horan Securities’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-142
Closed -$760 – 362
2023
Q2 		$760 Hold
142
– – ﹤0.01% 646
2023
Q1 		$1.4K Hold
142
– – ﹤0.01% 596
2022
Q4 		$2.65K Hold
142
– – ﹤0.01% 528
2022
Q3 		$3K Hold
142
– – ﹤0.01% 450
2022
Q2 		$3K Buy
142
+85
+149% +$2.4K ﹤0.01% 488
2022
Q1 		$2K Hold
57
– – ﹤0.01% 450
2021
Q4 		$3K Buy
+57
New +$4.57K ﹤0.01% 427
2021
Q2 		$9K Hold
80
– – 0.01% 315
2021
Q1 		$9K Buy
80
+23
+40% +$3.02K 0.01% 286
2020
Q4 		$6K Sell
57
-8
-12% -$1.06K ﹤0.01% 295
2020
Q3 		$9K Buy
65
+8
+14% +$1.67K 0.01% 219
2020
Q2 		$18K Buy
+57
New +$9.15K 0.02% 133

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Horan Securities's INO Position: Q3 2023 in Review

Horan Securities sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 142 shares — an estimated $760 sold.

Horan Securities first reported a position in INO in Q2 2020 and held it in 12 quarters. The position peaked at $18K in Q2 2020. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

  • Horan Securities reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Horan Securities sold 142 Inovio Pharmaceuticals shares in Q3 2023, an estimated $760.
  • Horan Securities first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 12 quarters.
  • Horan Securities's Inovio Pharmaceuticals position peaked at $18K in Q2 2020.
  • 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on Horan Securities's 13F filing for Q3 2023, filed 1 Nov 2023.